all report title image
  • Published On : Jan 2020
  • Code : CMI3354
  • Industry : Pharmaceutical
  • Pages : 160
  • Formats :

Oxytocic drugs used to stimulate uterine activity. It is also used to control bleeding after childbirth. It is injected into a muscle, or given as an infusion into a vein. Natural oxytocin is prepared by extracting from the pituitary glands of the animals.

The global oxytocic pharmaceuticals market is estimated to account for US$ 173.1 Mn in terms of value by the end of 2027.

Global Oxytocic Pharmaceuticals Market: Drivers

Increasing childbirth using labor induction is expected to boost growth of the global oxytocic pharmaceuticals market over the forecast period. For instance, according to National Perinatal Information Center’s January 2019 report, induction of labor rates increased by 40% during 1997-2017 in the U.S.

Moreover, higher prevalence of postpartum hemorrhage is also expected to aid in growth of the market. For instance, according to the study, ‘Incidence and risk factors for postpartum hemorrhage among transvaginal deliveries at a tertiary perinatal medical facility in Japan’, published in the journal PLoS One in January 2019, the incidence of postpartum hemorrhage was 8.7%, and of severe postpartum hemorrhage was 2.1%.

Asia Pacific region held dominant position in the global oxytocic pharmaceuticals market in 2019, accounting for 58.1% share in terms of value, followed by 2027.

Figure 1. Global Oxytocic Pharmaceuticals Market Value (US$ Mn), by Region, 2019

Oxytocic Pharmaceuticals  | Coherent Market Insights

Global Oxytocic Pharmaceuticals Market: Restraints

Availability of alternative drugs is expected to hinder growth of the global oxytocic pharmaceuticals market. Some of the alternatives for oxytocic pharmaceuticals misoprostol and magnesium sulphates. The World Health Organization (WHO) recommends misoprostol as a low-cost, evidence-based alternative to oxytocin.

Moreover, quality issues associated with oxytocin preparations are also expected to hinder growth of the market. Several manufacturers are not obtaining WHO prequalification for manufacturing of oxytocin products, which leads to production of substandard quality of drugs in the market.

Global Oxytocic Pharmaceuticals Market: Opportunities

Increasing focus of achieving mortality ratio of less than 70 per 100 000 live births in under-resourced regions is expected to offer lucrative growth opportunities for players in the market. For instance, according to Maternal Mortality: 1990 to 2015 Estimates by WHO, UNICEF, UNFPA, World Bank Group and the United Nations Population Division, Sub-Saharan Africa recorded the highest ratio or maternal mortality, at 555 per 100, 000 live births, from 1990 to 2015. Moreover, the United Nations is focused on achieving the Sustainable Development Goals 2015 - 2030 global maternal mortality ratio target of less than 70 per 100 000 live births.

Moreover, R&D in use of oxytocin at lower doses following caesarean section is expected to boost demand for oxytocin pharmaceuticals.

Postpartum Hemorrhage segment in the global oxytocic pharmaceuticals market was valued at US$ 62.7 Mn in 2019 and is expected to reach US$ 136.2 Mn by 2027 at a CAGR of 10.2% during the forecast period.

Market Trends/Key Takeaways

Market players require WHO prequalification for the products that are to be supplied to the international organizations. Manufacturers who adhere to the WHO’s prequalification may have greater possibility to gain larger market share than the non-prequalified manufacturers.

Increasing adolescent pregnancies in Latin America is expected to lead to high demand for oxytocics for labor or abortion in the region. For instance, according to Pan American Health Organization (PAHO), the U.N. children’s agency (UNICEF), and the U.N. Population Fund (UNFPA), there were 66.5 births per 1,000 girls aged 15 to 19 from 2010 to 2015 in Latin America compared to 46 births per 1,000 girls in the same age group worldwide.

Global Oxytocic Pharmaceuticals Market: Competitive Landscape

Major players operating in the global oxytocic pharmaceuticals market include, Fresenius Kabi AG, Biofutura SpA, Baxter Healthcare Corporation, Pfizer Inc., Ferring B.V., Novartis AG, and Teva Pharmaceutical Industries Ltd.

Global Oxytocic Pharmaceuticals Market: Competitive Landscape

Key players in the market are focused on product launch to expand their product portfolio. For instance, in July 2019, Dr. Reddy’s Laboratories launched Carboprost Tromethamine Injection USP, 250mcg/mL (1mL), a generic version of Hemabate (Pfizer).

In May 2018, Granules Pharmaceuticals, Inc., the wholly owned subsidiary of Granules India Ltd. partnered with West-Ward Pharmaceuticals Corp., a wholly-owned subsidiary of Hikma Pharmaceuticals PLC, to launch the generic version of Methylergonovine Maleate Tablets, USP, 0.2mg, the generic equivalent to Methergine.

Oxytocic drugs are administered intravenously and intramuscularly to stimulate uterine contractions during labor induction for normal child birth and control bleeding after childbirth. Administration of Oxytocic drugs help in both prevention and treatment of postpartum hemorrhage. According to the American College of Obstetricians and Gynecologists (ACOG) prophylactic administration of uterotonic agents to prevent uterine atony is recommended. Furthermore, increasing childbirth using labor induction is expected to boost growth of the global oxytocic pharmaceuticals market over the forecast period.

Key features of the study:

  • This report provides in-depth analysis of the Global Oxytocic Pharmaceuticals market  and provides market size (US$ million) and compound annual growth rate (CAGR %) for the forecast period (2019–2027), considering 2018 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by key players
  • It profiles key players in the global Oxytocic Pharmaceuticals market  based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include, Fresenius Kabi AG, Biofutura SpA, Baxter Healthcare Corporation, Pfizer Inc., Ferring B.V., Novartis AG, and Teva Pharmaceutical Industries Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global Oxytocic Pharmaceuticals market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Oxytocic Pharmaceuticals market

Detailed Segmentation:

  • Global Oxytocic Pharmaceuticals Market, By Indication:
    • Abortion Induced Incomplete
    • Inevitable Abortion
    • Postpartum Hemorrhage
    • Labor Induction
    • Labor Arrest
  • Global Oxytocic Pharmaceuticals Market, By Route of Administration:
    • Intramuscular
    • Intravenous Injection/Infusion
  • Global Oxytocic Pharmaceuticals Market, By Source of Origin:
    • Synthetic Oxytocin
    • Natural Oxytocin (Animal Pituitary Extract)
  • Global Oxytocic Pharmaceuticals Market, By End User:
    • Hospitals
    • Maternity Clinics
  • Global Oxytocic Pharmaceuticals Market, By Region:
    • North America
      • By Indication:
        • Abortion Induced Incomplete
        • Inevitable Abortion
        • Postpartum Hemorrhage
        • Labor Induction
        • Labor Arrest
      • By Route of Administration
        • Intramuscular
        • Intravenous Injection/Infusion
      • By Source of Origin
        • Synthetic Oxytocin
        • Natural Oxytocin (Animal Pituitary Extract)
      • By End User
        • Hospitals
        • Maternity Clinics
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Indication:
        • Abortion Induced Incomplete
        • Inevitable Abortion
        • Postpartum Hemorrhage
        • Labor Induction
        • Labor Arrest
      • By Route of Administration
        • Intramuscular
        • Intravenous Injection/Infusion
      • By Source of Origin
        • Synthetic Oxytocin
        • Natural Oxytocin (Animal Pituitary Extract)
      • By End User
        • Hospitals
        • Maternity Clinics
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Indication:
        • Abortion Induced Incomplete
        • Inevitable Abortion
        • Postpartum Hemorrhage
        • Labor Induction
        • Labor Arrest
      • By Route of Administration
        • Intramuscular
        • Intravenous Injection/Infusion
      • By Source of Origin
        • Synthetic Oxytocin
        • Natural Oxytocin (Animal Pituitary Extract)
      • By End User
        • Hospitals
        • Maternity Clinics
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Indication:
        • Abortion Induced Incomplete
        • Inevitable Abortion
        • Postpartum Hemorrhage
        • Labor Induction
        • Labor Arrest
      • By Route of Administration
        • Intramuscular
        • Intravenous Injection/Infusion
      • By Source of Origin
        • Synthetic Oxytocin
        • Natural Oxytocin (Animal Pituitary Extract)
      • By End User
        • Hospitals
        • Maternity Clinics
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Indication:
        • Abortion Induced Incomplete
        • Inevitable Abortion
        • Postpartum Hemorrhage
        • Labor Induction
        • Labor Arrest
      • By Route of Administration
        • Intramuscular
        • Intravenous Injection/Infusion
      • By Source of Origin
        • Synthetic Oxytocin
        • Natural Oxytocin (Animal Pituitary Extract)
      • By End User
        • Hospitals
        • Maternity Clinics
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Indication:
        • Abortion Induced Incomplete
        • Inevitable Abortion
        • Postpartum Hemorrhage
        • Labor Induction
        • Labor Arrest
      • By Route of Administration
        • Intramuscular
        • Intravenous Injection/Infusion
      • By Source of Origin
        • Synthetic Oxytocin
        • Natural Oxytocin (Animal Pituitary Extract)
      • By End User
        • Hospitals
        • Maternity Clinics
      • By Country:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Fresenius Kabi AG *
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Overview
      • Strategies
    • Biofutura SpA
    • Baxter Healthcare Corporation
    • Pfizer Inc.
    • Ferring B.V.
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.

“*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The global oxytocic pharmaceuticals market is expected to reach US$ 173.1 Mn in terms of value by the end of 2027.
Major players operating in the global oxytocic pharmaceuticals market include Fresenius Kabi AG, Biofutura SpA, Baxter Healthcare Corporation, Pfizer Inc., Ferring B.V., Novartis AG, and Teva Pharmaceutical Industries Ltd.
Availability of alternative drugs is one of the major factors that is expected to hamper growth of the market over the forecast period.
The increasing childbirth using labor induction is one of the major factors that is expected to propel growth of the market over the forecast period.
Rising preference of physicians for IV bolus oxytocin during cesarean conditions is one of the major trends that has been observed in the market.
Among regions, Asia Pacific is expected to hold a dominant position in the global oxytocic pharmaceuticals market in 2019, accounting for 58.1% share, in terms of value.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo